MagQu LLC

MagQu, Inc

Most technologies currently utilized for the diagnosis of Alzheimer's and Parkinson's disease are not sensitive enough to perform early detection and need to obtain central spinal fluid (CSF) samples from patients, which is invasive and painful. 

MagQu develops highly sensitive, blood-based assays for the early detection of Alzheimer's and Parkinson's diseases using its novel immunoMagnetic Reduction (IMR) technology. Currently, MagQu LLC USA is only able provide the testing services for research laboratories. In the future, once the IVD certification is approved by the FDA, we will be able to perform medical diagnosis for patients in the US as well.